Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis

Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis

BACKGROUND: Reduction in lesional, activated T cells induces improvement in psoriatic plaques. Galiximab (IDEC-114), an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 111(2004), 1 vom: 01. Apr., Seite 28-37
1. Verfasser: Gottlieb, Alice B (VerfasserIn)
Weitere Verfasser: Kang, Sewon, Linden, Kenneth G, Lebwohl, Mark, Menter, Alan, Abdulghani, Ahsan A, Goldfarb, Michael, Chieffo, Nicole, Totoritis, Mark C
Format: Aufsatz
Sprache:English
Veröffentlicht: 2004
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Clinical Trial Clinical Trial, Phase I Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Antibodies, Monoclonal galiximab S9OX9692ZB